IO Biotech, a clinical-stage biopharma company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has dosed the first patient in its phase 1 bladder cancer trial.
Regeneron (REGN) Announces FDA Approval of Libtay in Combination with Chemotherapy for Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor.